Robert J. Decker net worth and biography

Robert Decker Biography and Net Worth

Robert J. Decker holds the position of Chief Accounting Officer of Johnson & Johnson.

Mr. Decker received an undergraduate degree from Rider University.

What is Robert J. Decker's net worth?

The estimated net worth of Robert J. Decker is at least $2.74 million as of November 18th, 2022. Mr. Decker owns 15,473 shares of Johnson & Johnson stock worth more than $2,742,435 as of November 26th. This net worth estimate does not reflect any other investments that Mr. Decker may own. Learn More about Robert J. Decker's net worth.

How old is Robert J. Decker?

Mr. Decker is currently 50 years old. There are 5 older executives and no younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Mr. Alex Gorsky, Exec. Chairman, who is 62 years old. Learn More on Robert J. Decker's age.

How do I contact Robert J. Decker?

The corporate mailing address for Mr. Decker and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400. Learn More on Robert J. Decker's contact information.

Has Robert J. Decker been buying or selling shares of Johnson & Johnson?

During the last ninety days, Robert J. Decker has sold $2,962,400.00 in Johnson & Johnson stock. Most recently, Robert J. Decker sold 16,928 shares of the business's stock in a transaction on Friday, November 18th. The shares were sold at an average price of $175.00, for a transaction totalling $2,962,400.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company's stock, valued at $2,707,775. Learn More on Robert J. Decker's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Director ), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), Kathryn Wengel (EVP), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 12 times. They sold a total of 319,488 shares worth more than $55,676,151.09. The most recent insider tranaction occured on November, 22nd when EVP Jennifer L Taubert sold 76,923 shares worth more than $13,598,447.94. Insiders at Johnson & Johnson own 0.4 % of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 11/22/2022.

Robert J. Decker Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2022Sell16,928$175.00$2,962,400.0015,473View SEC Filing Icon  
5/26/2022Sell8,462$180.00$1,523,160.0015,473View SEC Filing Icon  
12/7/2021Sell5,000$163.21$816,050.00View SEC Filing Icon  
See Full Table

Robert J. Decker Buying and Selling Activity at Johnson & Johnson

This chart shows Robert J Decker's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $177.24
Low: $176.86
High: $178.12

50 Day Range

MA: $168.84
Low: $160.20
High: $177.01

2 Week Range

Now: $177.24
Low: $155.72
High: $186.69

Volume

3,056,125 shs

Average Volume

6,149,952 shs

Market Capitalization

$463.39 billion

P/E Ratio

24.69

Dividend Yield

2.55%

Beta

0.57